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ABSTRACT 
The detection of human papillomavirus (HPV) type 16 early genes: E7, E5, and the late gene: 
Ll was attempted in 42 uterine cervical neoplasia (35 cervical carcinomas and 7 cervical dyspla-
sias) using the polymerase chain reaction (PCR) method. Consequently, E7 gene was detected 
in 19 (54.3%) of 35 carcinomas and in 5 (71.4%) of 7 dysplasias, E5 gene was detected in 7 
(20.0%) of 35 carcinomas and in 5 (71.4%) of 7 dysplasias, Ll gene was detected in 18 (51.4%) 
of 35 carcinomas and in 5 (71.4%) of 7 dysplasias, respectively. 
In order to elucidate the transcriptional pattern of HPV type 16 in each of the clinical stages, 
the expression of mRNA for E7, E5 and Ll genes was examined in HPV DNA positive cases 
using the reverse transcriptase polymerase chain reaction (RT-PCR) method. E7 gene mRNA 
was detected in 18 (94.7%) of 19 cervical carcinomas, whereas E5 and Ll genes mRNAs were 
detected in only 4 (57.1 %) of 7 and in one (5.6%) of 18 carcinomas respectively. In cervical dys-
plasias, E7, E5 and Ll genes mRNA were detected in all cases. E7, E5 and Ll genes were 
transcriptionally active in all dysplasias, whereas E5 and Ll genes were not always transcrip-
tionally active in carcinomas. 
These results suggest that the HPV type 16 early gene E7 is present preferentially as in-
tegrated form and transcriptionally active in the carcinoma cell, and plays an important role 
in the development of malignancy. On the other hand, E5 and Ll genes are present and tran-
scribed in the dysplasia cell but their transcriptional activity is less frequent in the carcinoma cell. 
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Human papillomavirus (HPV) is a member of the 
papovavirus family and known as an etiologic agent 
of skin and mucocutaneous tumorigenesis in the hu-
man anogenital area. Recent investigations have 
revealed that some types of HPV, mostly type 16 
and 18, are demonstrated frequently in uterine cer-
vical neoplasia and associated with carcinogenesis 
of uterine cervix4•7•22•24). There has been increasing 
evidence that HPV DNA exists as an integrated 
form in advanced carcinoma, whereas it commonly 
exists as an episomal form in dysplasia 5•23). 
However, little is known about the function and sig-
nificance of each of the integrated HPV genes in 
carcinogenesis of the uterine cervix. 
these genes by reverse transcriptase polymerase 
chain reaction (RT-PCR) to ascertain whether or 
not integrated viral sequences are actively tran-
scribed. In addition, Northern blot hybridization 
which is the standard method for analysis of mRNA 
expression was compared with RT-PCR to deter-
mine their usefulness in the detection of HPV type 
16 mRNA. 
In view of these findings, it is important to ana-
lyze the physical state of HPV genomes and the 
alteration of their transcriptional pattern at each 
stage of malignancy. This study was undertaken to 
fulfill two purposes. The first aim was to examine 
the existence of HPV type 16 early genes: E7, E5; 
and late gene: Ll DNA in uterine cervical neopla-
sia by polymerase chain reaction (PCR), and these-
cond was to analyze the expression of mRNA of 
MATERIALS AND METHODS 
Tissue specimens: Cervical carcinoma and dyspla-
sia specimens were taken from forty-two patients 
who underwent abdominal total hysterectomy in the 
Department of Obstetrics and Gynecology, Hiroshi-
ma University School of Medicine (Table 1). These 
included 8 stage II and 14 stage I cervical carcino-
mas, 13 carcinomas in situ (CIS) and 7 severe dys-
plasias. Tissue specimens were frozen in liquid 
nitrogen immediately after surgical removal and 
stored at -80°C until use. A part of the tissue 
was fixed in 10% formalin and diagnosed 
histopathologically. 
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Table 1. Clinical features and results of detection of HPV type 16 DNA (mRNA) in subjects studied 
case age stage histology 
HPV 16 DNA (mRNA *) 
E7 E5 Ll 
1 31 dys +(+) +(+) +(+) 
2 43 dys +(+) +(+) +(+) 
3 42 dys +(+) +(+) +(+) 
4 35 dys 
5 41 dys 
6 54 dys +(+) +(+) +(+) 
7 33 dys +(+) +(+) +(+) 
8 30 0 Le +(+) +(-) 
9 35 0 Le +(+) +(-) 
10 46 0 Le +(+) +(-) +(-) 
11 43 0 Le +(+) +(-) 
12 37 0 Le +(+) +(-) 
13 51 0 Le +(+) +(-) +(-) 
14 49 0 Le 
15 49 0 Le 
16 40 0 Le +(+) +(-) 
17 42 0 Le +(+) +(+) +(+) 
18 61 0 Le 
19 47 0 Le +(+) +(-) 
20 73 0 Le 
21 33 Ia Ade 
22 42 Ia LNK +(+) +(+) +(-) 
23 41 Ia LNK 
24 62 Ia LNK 
25 55 lb LNK +(+) +(-) 
26 38 lb LK +(+) 
27 42 lb LNK +(+) +(-) 
28 66 lb LNK +(+) +(-) 
29 41 lb LK +(+) +(+) +(-) 
30 62 lb Ade 
31 43 lb LNK 
32 47 lb LNK +(+) +(+) +(-) 
33 54 lb LNK +(-) +(-) +(-) 
34 53 lb LNK 
35 64 Ila LK 
36 42 Ila Ade 
37 58 Ilb LK 
38 54 Ilb LNK +(+) +(-) 
39 47 Ilb LNK 
40 69 Ilb LNK 
41 39 Ilb LNK +(+) +(-) 
42 60 Ilb LK 
LNK: squamous cell carcinoma large cell non-keratinizing type 
LK: squamous cell carcinoma large cell keratinizing type 
Ade: adenocarcinoma, Le: carcinoma in situ large cell type 
* Detection of HPV type 16 mRNA by RT-PCR shown in parentheses 
DNA preparation: DNA was extracted from extracted with phenol and then with a mixture of 
formalin-fixed paraffin-embedded blocks of surgical 24 parts of chloroform and one part of isoamyl al-
specimens2>. The blocks were cut into sections 10 cohol. Sodium acetate was added to each sample 
µm thick and 10 or more sections were collected. and DNA was precipitated by 2.5 volumes of 
One section was saved for microscopic examina- ethanol. The specimen was kept overnight at 
tions. After deparaffinization by 100% xylene and -30°C, and after centrifugation the pellet was 
rehydration by 100% and 90% ethanol, the speci- washed with 80% ethanol and resuspended in 
men was suspended in 10 mM Tris-HCl (pH 8.0), H20. 
1 mM EDTA, and 100 mM NaCl containing 0.5% 
sodium dodecyl sulfate (SDS) and proteinase K (200 PCR: The PCR was performed with Gene-Amp Kit 
µg/ml) at 37°C for 2 days. Subsequently, DNA was (Perkin-Elmer Cetus, Norwalk, CT. U.S.A.). 
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E7 forward reverse 
544 
606 625 701 720 
115 bp 
E5 forward reverse 
3863 3867 3886 3998 4017 
151 bp 
L1 forward reverse 
5526 6027 6046 6160 6079 
153 bp 
E7 forward : 5'GCAACCAGAGACAACTGATC 
reverse : 5'ATTGTAATGGGCTCTGTCCG 
E5 forward : 5'GCATCCACAACATT ACTGGC 
reverse : 5' AACGCAGAGGCTGCTGTTAT 
L1 forward: 5'AATGCTAGTGCTTATGCAGC 
reverse : 5' ATTTACTGCAACATTGGTAC 
Fig. 1. Sequence of E7, E5 and Ll primers and 
locations in HPV type 16 genome. 
The E7, E5 and Ll primers of HPV type 16 are 
shown in Fig. 1. These primers were synthesized 
by a DNA synthesizer (Wakunaga Pharm. Co.). Ll 
primers were made according to the sequence 
described by Cornelissen et al12>. PCR using the 
E7, E5 and Ll primers yielded 115bp, 151bp and 
153bp fragments, respectively. 
One microgram of extracted DNA was denatured 
at 94 °C for 10 min, and added to a 50 µl of PCR 
solution (10 mM Tris-HCl pH8.3, 50 mM KCl, 1.5 
mM MgC12, 0.01 % gelatin) containing 0.2 mM 
each of dATP, dGTP, dCTP, dTTP, 0.2 µM each 
of the primers (forward, reverse) and 2.5 units of 
Taq-DNA polymerase (TAKARA). The mixture was 
incubated at 94 °C for 1 min to denature the DNA, 
the primers were allowed to anneal to the DNA at 
55 ° C for 2 min and extension was performed at 
72 ° C for 2 min. Thirty cycles of amplification were 
repeated by Thermal Cycler (Perkin-Elmer Cetus). 
After amplification, 10 µl of the reaction mixture 
was subjected to electrophoretic analysis on 3 % 
NuSieve agarose (FMC, Rockland, ME. U.S.A.) and 
stained with ethidium bromide. 
RNA preparation: RNA was extracted by the 
guanidium isothiocyanate I cesium chloride 
method11>. Solution 1 (4M guanidinium iso-
thiocyanate, 5mM sodium citrate pH 7.0, 0.5% 
sarkosyl and 1 % 2-mercaptoethanol) was added to 
tissue specimens and dispersion was performed by 
homogenizer. One gram of cesium chloride was ad-
ded to each 2.5 ml of homogenate and the 
homogenate was layered onto 2.5 ml of 5.7M CsCl 
in 0.lM EDTA (pH 7.5) in a centrifuge tube. Cen-
trifugation was performed at 35,000 rpm for 14 
hours at 20°C in a Beckman SW-40. After the su-
pernatant was discarded, the pellet of RNA was 
dissolved in solution 2 (10 mM Tris-HCl, pH 7.4, 
5mM EDTA and 1 % SDS). A mixture of chloro-
form and 1-butanol (4:1) was added and the aque-
ous phase was transferred to a fresh tube. Three 
molar sodium acetate and 2.2 volumes of ethanol 
were added to the tube which was stored overnight 
at -20°C. The RNA was recovered by centrifuga-
tion and dissolved in H20. 
RT-PCR: The reverse transcription of RNA was 
performed with AMV Reverse Transcriptase Sys-
tem (BRL, Gaithersburg, U.S.A.) and the PCR was 
performed with Gene-Amp Kit. Two point five 
micro liters of nucleotide solution (1 OmM dATP, 
dGTP, dTTP and dCTP in lOmM Tris-HCl, pH 7.5) 
was added to 2µg of RNA and lyophilized, and then 
the following solutions were added to the samples: 
5µ1 of 250mM KCl, 5µ1 of reverse transcription 
buffer (500mM Tris-HCl, pH 8.3, 50mM MgC12, 
50mM DTT), 5µ1 of 100 µg/ml oligo dT 12-ls solu-
tion, 5µ1 of 250 µg/ml actinomycin D solution, 5 
units of AMV reverse transcriptase. The reaction 
mixture was incubated at 37°C for 1 hour, and 2µ1 
of the sample was subjected to PCR. 
Northern blot hybridization: Ten micrograms of 
total RNA from 30 cases were electrophoresed on 
1 % agarose gel containing 6% formaldehyde and 
blotted onto nitrocellulose filters. Filters were 
baked for 2 hours at 80 ° C under vacuum. After 
pre-hybridization, hybridization was performed at 
42°C for 16 hours. The hybridization solution con-
tained O.lM PIPES-NaOH, pH6.8, 0.65M NaCl, 
5 x Denhardt' s solution (1 x Denhardt' s consisted of 
0.02% (w/v) each of bovine serum albumin, Ficoll, 
and polyvinyl pyrrolidine), 0.1 % SDS, 50% 
deionized formamide, 10% Dextran sulfate and 100 
µglml salmon sperm DNA. 
The HPV type 16 DNA probe was labeled with 
[ 32P]-dCTP by multiprime DNA labeling system 
(Amersham, Tokyo, Japan). 
After hybridization, filters were washed twice in 
0.1 x SSC-0.1 o/oSDS (1 x SSC is 0.15M NaCl and 
0.015M sodium citrate) for 30 min at room temper-
ature, then washed twice in 0.1 x SSC-0.1 %SDS for 
60 min at 65°C and rinsed in 0.1 x SSC. Filters 
were autoradiographed overnight at -80 ° C with 
Kodak XAR-5 films with an intensifying screen. 
Slot blot hybridization: Five microliters of the 
PCR and RT-PCR product were transferred to a 
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nitrocellulose filter membrane. Hybridization and 
washing procedures were performed as described 
above. 
RE~ULTS 
Analysis of the presence of E7, E5 and Ll DNAs 
of HPV type 16 were performed in 42 uterine cer-
vical neoplasia cases (Table 1) and representative 
cases among these are shown in Fig. 2. The 115bp 
and 153bp bands of E7 and Ll DNA in case 16, 
and 115bp, 151bp and 153bp bands in case 17 were 
153b~ 
15lb-
115b_/ 
case 16 
E7 E5 Ll 
case 17 
E7 E5 Ll 
demonstrated. The percent positive for E7, E5 and 
Ll in each stage of cervical neoplasia are summa-
rized in Table 2. In the cases of dysplasias that 
were positive in viral DNA, all of the E7, E5 and 
Ll genes were detected simultaneously, whereas 
E5 was not always detected in the viral DNA-
positive carcinoma cases. The frequency of HPV 
type 16 DNA in the advanced cervical carcinomas 
(stage II) was lower (E7: 25.0%, E5: 0%, Ll: 
25.0%) than those in the early stages (stage O: E7: 
69.2%, E5: 23.1 %, Ll: 69.2% and stage I: E7: 
case 18 
E7 E5 Ll s 
-267b 
-80b 
Fig. 2. Detection of E7, E5 and Ll DNAs of HPV type 16 in uterine cervical carcinoma. After PCR, 
10µ1 of the sample was subjected to electrophoretic analysis and stained with ethidium bromide as described 
in Materials and Methods. 
Table 2. Frequency of E7, E5 and Ll DNA detected in cervical neoplasia by clinical stage 
E7 E5 Ll 
dysplasia 71.4% (5/7) 71.4% (5/7) 71.4% (5/7) 
carcinoma 54.3% (19/35) 20.0% (7/35) 51.4% (18/35) 
stage 0 69.2% (9/13) 23.1 % (3/13) 69.2% (9/13) 
stage I 57.1 % (8/14) 28.6% (4/14) 50.0% (7/14) 
stage II 25.0% (2/8) 0% (0/8) 25.0% (2/8) 
Stages in carcinoma according to the criteria of the International Federation of Gynecology and Obstetrics (1971). 
Number of positive/total shown in parentheses. 
153b~ 
15lb-
115b_/ 
case 16 
E7 E5 Ll 
case 17 
E7 E5 Ll 
case 18 
E7 E5 Ll s 
-267b 
-80b 
Fig. 3. Detection of E7, E5 and Ll mRNAs of HPV type 16 by RT-PCR. After amplification by RT-PCR, 
10 µl of the sample was subjected to electrophoretic analysis and stained with ethidium bromide as described 
in Materials and Methods. 
Table 3. Expression of mRNA for each gene in HPV-DNA positive cases 
E7 E5 Ll 
dysplasia 100% (5/5) 100% (5/5) 100% (5/5) 
carcinoma 94. 7% (18/19) 57.1 % (417) 5.6% (1/18) 
stage 0 100% (9/9) 33.3% (1/3) 11.1 % (119) 
stage I 87.5% (7/8) 75.0% (3/4) 0% (0/7) 
stage II 100% (2/2) - (0/0) 0% (0/2) 
See footnotes to Table 2. 
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57.1 %, E5: 28.6%, Ll: 50.0%). 
To elucidate the expression of the viral genes in 
carcinomas of each clinical stage, mRNAs for E7, 
E5 and Ll genes were examined by RT-PCR for 
the cases of viral DNA positive (Fig. 3 and Table 
3). E7 mRNA was detected in 18 (94.7%) of 19 E7 
DNA positive carcinomas, while E5 and Ll mRNAs 
were detected only in 4 (57.1 %) of 7 and in one 
(5.6%) of 18 carcinomas positive for these DNAs, 
respectively. In cases of dysplasia, E7, E5 and Ll 
mRNA were detected in all of the HPV DNA posi-
tive cases. HPV mRNA was not detected in the 
1 2 3 4 5 6 7 8 9 10 
18S-
28S-
JJ-actin 
Fig. 4. HPV type 16 mRNA detected by Northern 
blot hybridization. The method is described in Materi-
als and Methods. Lanes: 1-10; case 11, 12, 22, 23, 
13, 29, 14, 15, 16 and 30 respectively. {J-actin probe 
applied as an internal control. 
E7 E5 L1 
16 
17 ... 
18 
c 
Fig. 5. Slot blot hybridization of RT-PCR product. A 
5µ1 volume of the sample was applied to nitrocellulose 
filter, hybridized with 32P labeled probe DNA, 
washed, and autoradiographed as described in Materi-
als and Methods. The three upper lanes (16, 17, 18) 
correspond to case 16, 17 and 18 in Table 1. E7 in 
case 16 and E7, E5 and Ll in case 17 showed posi-
tive signals, which corresponded to the results of RT-
PCR. The PCR products from HPV type 16 DNA 
were used as a positive control (lane C). 
HPV DNA negative cases. 
In Northern blot hybridization analysis, HPV type 
16 mRNA was detected in 6 cases (8, 9, 10, 17, 
22, 29) of 30 cervical carcinomas (from case 8 to 
case 30 and from case 35 to case 41 in Table 1). 
Representative cases are shown in Fig. 4. Two 
major transcripts of about 4.2kb and l.8kb and 
some minor transcripts were detected in the HPV 
type 16 positive cases. These bands corresponded 
to the previously reported HPV type 16 
transcripts14). The ,6-actin probe was employed as 
an internal control. Transcription of viral genes was 
detectable in only 6 (20.0%) cases among these 30 
cervical carcinomas by Northern blot hybridization, 
while 17 (56.7%) cases were positive by RT-PCR. 
Slot blot hybridization was applied to confirm 
whether the PCR and the RT-PCR products were 
derived from the HPV type 16 genes (Fig. 5). The 
results of slot blot hybridization revealed that all 
the cases positive in PCR and RT-PCR were also 
positive in the slot blot hybridization. 
DISCUSSION 
By analyzing HPV type 16 DNA in uterine cer-
vical neoplasia, it was demonstrated that all of the 
E7, E5 and Ll genes were detected in 71.4% of 
dysplasia, while the frequencies of detection of E7, 
E5 and Ll genes decreased and varied in carcino-
mas. E7 (54.3%) and Ll (51.4%) genes were rela-
tively well conserved in the carcinoma cells than 
E5 gene (20.0%). These findings may support the 
hypothesis that HPV type 16 DNA is integrated 
into the cellular DNA in carcinoma, while in dys-
plasia, HPV DNA is present as a complete viral 
gene in the episomal state8•15•16). In view of the as-
sociation of HPV type 16 DNA with clinical stage 
of uterine cervical neoplasia, the advanced carcino-
ma showed a lower frequency of HPV type 16 
DNA (Table 2). This result suggests that HPV type 
16 may be not related to maintenance of malignan-
cy, but related to initiation of the process. 
Futhermore, in the study to elucidate the tran-
scriptional pattern associated with clinical stages, 
the expression of mRNA for E7, E5 and Ll genes 
was transcriptionally active in all the dysplasia 
cases. As for the carcinoma cases, E7 gene was 
transcribed in all E7 DNA positive cases with the 
exception of one case of stage I carcinomas. The 
reason why E 7 gene was not transcribed in this 
case is unclear. 
In this study, RT-PCR was used to analyze HPV 
type 16 mRNA, since it was difficult to obtain suffi-
cient amounts of RNA from uterine cervical neopla-
sia. In order to evaluate the utility of RT-PCR for 
detection of HPV type 16 mRNA, the sensitivity 
of RT-PCR was compared with that of Northern 
blot hybridization. HPV type 16 mRNA was detect-
ed in 17 (56.7%) of 30 cases by RT-PCR, whereas 
in only 6 (20.0%) of 30 cases by Northern blot 
hybridization. These results show that RT-PCR is 
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more sensitive than Northern blot hybridization and 
that RT-PCR is very useful in detection of HPV 
mRNA from small specimens. 
E 7 gene is considered to be the most well re-
tained among HPV type 16 genes in cervical 
carcinoma20), and in the course of development of 
malignancy E 7 gene is transcribed actively even 
though the alteration of transcriptional regulation 
might occur14•17). Wilczynski et al20) have suggested 
that E7 gene plays a role in the maintenance of 
the malignant state, while, Lehn et al1°) have 
reported that HPV type 16 may be a potential haz-
ard in the first step of the multistep development 
of cervical carcinomas and that the maintenance of 
the malignant nature may not depend on the con-
tinuous transcriptional activity of HPV type 16. In 
the present study, E7 DNA was less frequently de-
tected in advanced carcinoma, while transcription-
al activity of this gene was well conserved in all 
stages of carcinoma. These results suggest that E 7 
gene might be an initiator in the early stages of 
malignancy. The other early and late genes, such 
as E5 and Ll, were less retained than E7 and tran-
scriptionally unstable in carcinoma. E5 and Ll 
genes may be present as episomal form and tran-
scriptionally active in dysplasia. After integration 
they might become transcriptionally inactive and 
subsequently deleted in carcinomas. These findings 
suggest that E5 and Ll are not essential to the 
maintenance of the malignant state. The other 
genes should also be examined to clarify which 
genes of HPV type 16 are important in malignant 
conversion and maintenance of malignancy. 
Recent investigations have revealed that mul-
tistep genomic alteration may induce the malignant 
conversion of cells, and HPV type 16 plays an im-
portant role in the carcinogenesis of uterine cer-
vix not only by its own transforming activity9•13•18)_, 
but also by association with alteration of the on-
cogene and/or the tumor suppressor gene21). In 
some cervical carcinomas, HPV genomes have been 
integrated in regions of the human genome near 
the c-myc gene; cis-activation of the c-myc gene by 
inserted viral sequences might be involved in malig-
nant transformation1•3). Retinoblastoma (RB) gene 
product has been shown to form complexes with 
the HPV type 16 E7 protein. Consequently, inacti-
vation of the RB protein which has tumor suppres-
sor properties might occur6), and the HPV type 16 
E6 protein has been shown to bind to p53 protein, 
which is also tumor suppressor gene product, in a 
similar manner19). Therefore the investigation of 
the integration and expression of E6/E7 genes 
must be the most important elements in clarifying 
the role of HPV type 16 in multistep carcinogene-
sis and development of malignancy in the uterine 
cervix. 
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